Literature DB >> 7560182

P-glycoprotein positive, drug resistant invasive lymphoepithelial thymoma: treatment response to chemotherapy with cyclosporin and quinine.

J L Gala1, H Noël, J Rodhain, D F Ma, A Ferrant.   

Abstract

A case of invasive drug resistant thymoma, expressing P-glycoprotein, which showed noticeable clinical response to chemotherapy and the multidrug resistance modulating agents cyclosporin and quinine is reported. A 46 year old man presented with severe left shoulder pain and a diagnosis of invasive lymphoepithelial thymoma was made following chest x ray and a computed tomography scan. The patient underwent extensive chemotherapy without resolution of the tumour. More than 90% of the malignant epithelial cells were strongly positive for P-glycoprotein and based on this observation, cyclosporin and quinine were added to the chemotherapy regimen. The mediastinal mass completely resolved and the size of the pleural metastasis decreased substantially. The patient, however, died of an intercurrent infection. This case report highlights the feasibility and efficacy of using cyclosporin and quinine in combination with VAD chemotherapy in the treatment of invasive thymoma.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7560182      PMCID: PMC502726          DOI: 10.1136/jcp.48.7.679

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  10 in total

1.  Neoadjuvant chemotherapy, surgery, and postoperative radiation therapy for invasive thymoma.

Authors:  P Macchiarini; A Chella; F Ducci; B Rossi; C Testi; G Bevilacqua; C A Angeletti
Journal:  Cancer       Date:  1991-08-15       Impact factor: 6.860

2.  P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil.

Authors:  T P Miller; T M Grogan; W S Dalton; C M Spier; R J Scheper; S E Salmon
Journal:  J Clin Oncol       Date:  1991-01       Impact factor: 44.544

Review 3.  Clinical significance of P-glycoprotein in multidrug resistance malignancies.

Authors:  R J Arceci
Journal:  Blood       Date:  1993-05-01       Impact factor: 22.113

4.  Chemotherapy for advanced thymoma. Preliminary results of an intergroup study.

Authors:  P J Loehrer; C A Perez; L M Roth; A Greco; R B Livingston; L H Einhorn
Journal:  Ann Intern Med       Date:  1990-10-01       Impact factor: 25.391

5.  Chemotherapy of invasive thymoma.

Authors:  A Fornasiero; O Daniele; C Ghiotto; F Sartori; F Rea; M Piazza; L Fiore-Donati; P Morandi; S M Aversa; A Paccagnella
Journal:  J Clin Oncol       Date:  1990-08       Impact factor: 44.544

6.  Modulation of multidrug-resistant multiple myeloma by cyclosporin. The Leukaemia Group of the EORTC and the HOVON.

Authors:  P Sonneveld; B G Durie; H M Lokhorst; J P Marie; G Solbu; S Suciu; R Zittoun; B Löwenberg; K Nooter
Journal:  Lancet       Date:  1992-08-01       Impact factor: 79.321

7.  P-glycoprotein expression in human plasma cell myeloma: correlation with prior chemotherapy.

Authors:  T M Grogan; C M Spier; S E Salmon; M Matzner; J Rybski; R S Weinstein; R J Scheper; W S Dalton
Journal:  Blood       Date:  1993-01-15       Impact factor: 22.113

8.  An immunohistologic study of the epithelial components of 81 cases of thymoma.

Authors:  I Fukai; A Masaoka; T Hashimoto; Y Yamakawa; T Mizuno; O Tanamura; K Hirokawa; R Ueda
Journal:  Cancer       Date:  1992-05-15       Impact factor: 6.860

9.  Specificity and sensitivity of immunocytochemistry for detecting P-glycoprotein in haematological malignancies.

Authors:  J L Gala; J M McLachlan; D R Bell; J L Michaux; D D Ma
Journal:  J Clin Pathol       Date:  1994-07       Impact factor: 3.411

10.  The prognostic implication of thymoma histologic subtyping. A study of 80 consecutive cases.

Authors:  E Pescarmona; E A Rendina; F Venuta; C Ricci; L P Ruco; C D Baroni
Journal:  Am J Clin Pathol       Date:  1990-02       Impact factor: 2.493

  10 in total
  1 in total

1.  Cancer: a single disease with a multitude of manifestions?

Authors:  Peter Grandics
Journal:  J Carcinog       Date:  2003-11-18
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.